Sign in
ENVB Stock Price, Chart, Stats & News
Enveric Biosciences, Inc.
Save
Enveric Biosciences, Inc. (ENVB) does not currently pay a dividend.
895,518
Market cap
–
Current P/E
23.09x
Forward P/E
ENVB chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.07% |
ROA | -190.98% |
ROE | -283.41% |
D/E | – |
Interest coverage ratio | -73896.60x |
ENVB valuation
P/E | – |
P/S | – |
P/B | 0.14x |
P/CF | -0.07x |
P/FCF | -0.14x |
P/OCF | -0.07x |
PEG | -0.28x |
EV multiple | -0.61x |
About
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application.
Similar securities
Based on sector and market capitalization
Report issue